Quanterix Corporation (QTRX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, QTRX scores 23 out of 100 with a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC of -35% and FCF yield of 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 5/20 (Beta 1.0 with sector sensitivity); and Forensic Balance Sheet at 5/20 (Altman Z 0.2, Piotroski F 3/9, Debt/Equity 0.5). Taken together, the weakest pillars are the cash engine and insider conviction, meaning the business is not currently generating returns on capital or cash, and insider activity provides little supportive signal. For a prospective investor, the upside case rests on a turnaround in operating economics that the source data does not show yet; the valuation tradeoff is that a market cap of $148.7M against operating margin of -60% and net margin of -60% leaves little margin for error. The Altman Z of 0.2 and Piotroski F of 3/9 point to elevated financial distress and weak fundamental quality, which are the forensic risks the verdict flags. This is an analytical reading of the scores, not a recommendation.

Quanterix Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry. Per the profile, the company carries a market capitalization of $0.1B. The source data does not describe its product lines, customer base, or revenue model beyond the sector and industry classification. Reported revenue appears in the SEC financials, with FY 2025 revenue of $138.9M.

Per the SEC financials and market data, the company reported negative operating, net, and free cash flow across all three periods shown, with operating margin and net margin both at -60%. Gross margin is 46.8%, so the losses are driven by operating costs rather than gross profitability. ROIC is -35% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Cash declined from $56.7M in FY 2024 to $29.8M in FY 2025.

• Earnings date: A headline reports that Quanterix will report third quarter 2026 financial results on November 9, 2026 (marked YELLOW, MARKET WIRE).
• China regulatory approvals: Headlines report that Quanterix and Innovita expanded IVD access in China with National Medical Products Administration approvals (YELLOW), and that a partner received China approval for neurology tests (GREEN, CATALYST).
• General coverage: Additional wire items are generic market-coverage pieces and a seasonal returns chart with no specific catalyst content in the summaries.
• Risk watch: The earnings release falls within the near-term window; the source summaries do not provide results or guidance.
• Proprietary signals: Per the Butterfly Supply-Chain Graph, none are present.

• What are the reported EPS, debt figures, and cash balances for FY 2023, since these are marked N/A or unavailable?
• What do the third quarter 2026 results (due November 9, 2026) show for revenue, margins, and cash burn?
• What drives the gap between the $0.1B market capitalization and the balance sheet indicators (Altman Z 0.2)?
• What is the commercial scale of the China approvals relative to total revenue?
• Which specific institutional holders and insider transactions underpin the whale-flow and insider-conviction pillar scores?